A Phase l Study to Evaluate the Safety of Colchicine
Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
Currently, there are no approved medications for the prevention and treatment of
radiation-induced dermatitis, or skin discoloration/burning due to radiation therapy, because
there is little evidence to guide treatment.
The purpose of the research is to better understand the factors associated with
radiation-induced dermatitis and to explore the efficacy of low-dose colchicine in reducing
the proportion of patients with radiation-induced dermatitis who undergo radiation treatment
for head and neck cancer. If you take part in the research, you will be asked to take 0.6 mg
once a day by mouth. The participants time in the study will take less than a minute a day to
take the pill and 20 minutes to complete survey questions during follow-up visits.